DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
SUVN-G3031 is an investigational drug.
There have been 7 clinical trials for SUVN-G3031. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Cognition Disorders, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Suven Life Sciences Limited and [disabled in preview].
There are two US patents protecting this investigational drug and fifty-six international patents.
Recent Clinical Trials for SUVN-G3031
|A Study to Evaluate Safety, and Efficacy of SUVN-G3031 in Patients With Narcolepsy With and Without Cataplexy||Suven Life Sciences Limited||Phase 2|
|Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects||Suven Life Sciences Limited||Phase 1|
|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects||Suven Life Sciences Limited||Phase 1|
Top disease conditions for SUVN-G3031
Top clinical trial sponsors for SUVN-G3031
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SUVN-G3031||Start Trial||Compounds as histamine H3 receptor ligands||Suven Life Sciences Limited (Hyderabad, IN)||Start Trial|
|SUVN-G3031||Start Trial||Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride||Suven Life Sciences Limited (Hyderabad, IN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SUVN-G3031||African Regional IP Organization (ARIPO)||3340||1989-12-31||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|